Search

Your search keyword '"Myhr-Eriksson, Kristina"' showing total 28 results
Start Over Author "Myhr-Eriksson, Kristina"
28 results on '"Myhr-Eriksson, Kristina"'

1. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI

Author

Richter, Johan, Lübking, Anna, Söderlund, Stina, Lotfi, Kourosh, Markevärn, Berit, Själander, Anders, Stenke, Leif, Deneberg, Stefan, Ahlstrand, Erik, Myhr-Eriksson, Kristina, Panayiotidis, Panayiotis, Gedde-Dahl, Tobias, Žáčková, Daniela, Mayer, Jiří, Olsson-Strömberg, Ulla, Mahon, Francois-Xavier, Saussele, Susanne, Hjorth-Hansen, Henrik, and Koskenvesa, Perttu

Published
2021
Full Text
View/download PDF

2. IFN-[alpha] with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Author

Huuhtanen, Jani, Ilander, Mette, Yadav, Bhagwan, Dufva, Olli M.J., Lahteenmaki, Hanna, Kasanen, Tiina, Klievink, Jay, Olsson-Stromberg, Ulla, Stentoft, Jesper, Richter, Johan, Koskenvesa, Perttu, Hoglund, Martin, Soderlund, Stina, Dreimane, Arta, Porkka, Kimmo, Gedde-Dahl, Tobias, Gjertsen, Bjorn T., Stenke, Leif, Myhr-Eriksson, Kristina, Markevarn, Berit, Lubking, Anna, Dimitrijevic, Andreja, Udby, Lene, Bjerrum, Ole Weis, Hjorth-Hansen, Henrik, and Mustjoki, Satu

Subjects
Drug therapy, Physiological aspects, Dosage and administration, Methods, Health aspects, Combination chemotherapy -- Methods -- Physiological aspects, Immune system -- Health aspects, Chronic myeloid leukemia -- Drug therapy -- Physiological aspects, Dasatinib -- Dosage and administration -- Physiological aspects, Interferon alpha -- Dosage and administration -- Physiological aspects, Chemotherapy, Combination -- Methods -- Physiological aspects
Abstract

Introduction Currently, the ultimate therapeutic goal in patients with chronic-phase chronic myeloid leukemia (CP-CML) is to achieve deep molecular remission, which would allow the discontinuation of tyrosine kinase inhibitor (TKI) [...], In chronic myeloid leukemia (CML), combination therapies with tyrosine kinase inhibitors (TKIs) aim to improve the achievement of deep molecular remission that would allow therapy discontinuation. IFN-[alpha] is one promising candidate, as it has long-lasting effects on both malignant and immune cells. In connection with a multicenter clinical trial combining dasatinib with IFN-[alpha] in 40 patients with chronic-phase CML (NordCML007, NCT01725204), we performed immune monitoring with single-cell RNA and T cell receptor (TCR) sequencing (n = 4, 12 samples), bulk TCR[beta] sequencing (n = 13, 26 samples), flow cytometry (n = 40, 106 samples), cytokine analyses (n = 17, 80 samples), and ex vivo functional studies (n = 39, 80 samples). Dasatinib drove the immune repertoire toward terminally differentiated NK and [CD8.sup.+] T cells with dampened functional capabilities. Patients with dasatinib-associated pleural effusions had increased numbers of [CD8.sup.+] recently activated effector memory T (Temra) cells. In vitro, dasatinib prevented CD3-induced cell death by blocking TCR signaling. The addition of IFN-[alpha] reversed the terminally differentiated phenotypes and increased the number of costimulatory intercellular interactions and the number of unique putative epitope-specific TCR clusters. In vitro IFN-[alpha] had costimulatory effects on TCR signaling. Our work supports the combination of IFN-[alpha] with TKI therapy, as IFN-[alpha] broadens the immune repertoire and restores immunological function.

Published
2022
Full Text
View/download PDF

3. P513: MOLECULAR PATTERN BY AGE AND OVERALL SURVIVAL IN ACUTE MYELOID LEUKEMIA: A POPULATION-BASED STUDY FROM THE SWEDISH AML REGISTRY.

Author

Juliusson, Gunnar, primary, Nilsson, Christer, additional, Lehmann, Sören, additional, Jädersten, Martin, additional, Wennström, Lovisa, additional, Fogelstrand, Linda, additional, Baliakas, Panagiotis, additional, Pandzic, Tatjana, additional, Cavelier, Lucia, additional, Eriksson, Anna, additional, Österroos, Albin, additional, Thunström, Anna, additional, Piauger, Benedicte, additional, Uggla, Bertil, additional, Ölander, Emma, additional, Orrsjö, Gustav, additional, Cammenga, Jörg, additional, Myhr-Eriksson, Kristina, additional, Willner Hjelm, Petter, additional, Deneberg, Stefan, additional, Fioretos, Thoas, additional, Höglund, Martin, additional, and Lazarevic, Vladimir, additional

Published
2023
Full Text
View/download PDF

4. IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Author

Huuhtanen, Jani, primary, Ilander, Mette, additional, Yadav, Bhagwan, additional, Dufva, Olli M.J., additional, Lähteenmäki, Hanna, additional, Kasanen, Tiina, additional, Klievink, Jay, additional, Olsson-Strömberg, Ulla, additional, Stentoft, Jesper, additional, Richter, Johan, additional, Koskenvesa, Perttu, additional, Höglund, Martin, additional, Söderlund, Stina, additional, Dreimane, Arta, additional, Porkka, Kimmo, additional, Gedde-Dahl, Tobias, additional, Gjertsen, Björn T., additional, Stenke, Leif, additional, Myhr-Eriksson, Kristina, additional, Markevärn, Berit, additional, Lübking, Anna, additional, Dimitrijevic, Andreja, additional, Udby, Lene, additional, Bjerrum, Ole Weis, additional, Hjorth-Hansen, Henrik, additional, and Mustjoki, Satu, additional

Published
2022
Full Text
View/download PDF

5. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Author

Höglund, Martin, Sandin, Fredrik, Hellström, Karin, Björeman, Mats, Björkholm, Magnus, Brune, Mats, Dreimane, Arta, Ekblom, Marja, Lehmann, Sören, Ljungman, Per, Malm, Claes, Markevärn, Berit, Myhr-Eriksson, Kristina, Ohm, Lotta, Olsson-Strömberg, Ulla, Själander, Anders, Wadenvik, Hans, Simonsson, Bengt, Stenke, Leif, and Richter, Johan

Published
2013
Full Text
View/download PDF

6. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors : Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study

Author

Dahlen, Torsten, Edgren, Gustaf, Ljungman, Per, Flygt, Hjalmar, Richter, Johan, Olsson-Strömberg, Ulla, Wadenvik, Hans, Dreimane, Arta, Myhr-Eriksson, Kristina, Zhao, Jingcheng, Sjalander, Anders, Höglund, Martin, Stenke, Leif, Dahlen, Torsten, Edgren, Gustaf, Ljungman, Per, Flygt, Hjalmar, Richter, Johan, Olsson-Strömberg, Ulla, Wadenvik, Hans, Dreimane, Arta, Myhr-Eriksson, Kristina, Zhao, Jingcheng, Sjalander, Anders, Höglund, Martin, and Stenke, Leif

Abstract

Tyrosine kinase inhibitors (TKIs) have profoundly improved the clinical outcome for patients with chronic myeloid leukemia (CML), but their overall survival is still subnormal and the treatment is associated with adverse events. In a large cohort-study, we assessed the morbidity in 1328 Swedish CML chronic phase patients diagnosed 2002-2017 and treated with TKIs, as compared to that in carefully matched control individuals. Several Swedish patient registers with near-complete nationwide coverage were utilized for data acquisition. Median follow-up was 6 (IQR, 3-10) years with a total follow-up of 8510 person-years for the full cohort. Among 670 analyzed disease categories, the patient cohort showed a significantly increased risk in 142 while, strikingly, no category was more common in controls. Increased incidence rate ratios/IRR (95% CI) for more severe events among patients included acute myocardial infarction (AMI) 2.0 (1.5-2.6), heart failure 2.6 (2.2-3.2), pneumonia 2.8 (2.3-3.5), and unspecified sepsis 3.5 (2.6-4.7). When comparing patients on 2nd generation TKIs vs. imatinib in a within-cohort analysis, nilotinib generated elevated IRRs for AMI (2.9; 1.5-5.6) and chronic ischemic heart disease (2.2; 1.2-3.9), dasatinib for pleural effusion (11.6; 7.6-17.7) and infectious complications, for example, acute upper respiratory infections (3.0; 1.4-6.0). Our extensive real-world data reveal significant risk increases of severe morbidity in TKI-treated CML patients, as compared to matched controls, particularly for 2nd generation TKIs. Whether this increased morbidity may also translate into increased mortality, thus preventing CML patients to achieve a normalized overall survival, needs to be further explored.

Published
2022
Full Text
View/download PDF

7. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Author

Simonsson, Bengt, Gedde-Dahl, Tobias, Markevärn, Berit, Remes, Kari, Stentoft, Jesper, Almqvist, Anders, Björeman, Mats, Flogegård, Max, Koskenvesa, Perttu, Lindblom, Anders, Malm, Claes, Mustjoki, Satu, Myhr-Eriksson, Kristina, Ohm, Lotta, Räsänen, Anu, Sinisalo, Marjatta, Själander, Anders, Strömberg, Ulla, Bjerrum, Ole Weiss, Ehrencrona, Hans, Gruber, Franz, Kairisto, Veli, Olsson, Karin, Sandin, Fredrik, Nagler, Arnon, Nielsen, Johan Lanng, Hjorth-Hansen, Henrik, and Porkka, Kimmo

Published
2011
Full Text
View/download PDF

9. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study

Author

Dahlén, Torsten, primary, Edgren, Gustaf, additional, Ljungman, Per, additional, Flygt, Hjalmar, additional, Richter, Johan, additional, Olsson‐Strömberg, Ulla, additional, Wadenvik, Hans, additional, Dreimane, Arta, additional, Myhr‐Eriksson, Kristina, additional, Zhao, Jingcheng, additional, Själander, Anders, additional, Höglund, Martin, additional, and Stenke, Leif, additional

Published
2022
Full Text
View/download PDF

10. Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study

Author

Flygt, Hjalmar, primary, Söderlund, Stina, additional, Stentoft, Jesper, additional, Richter, Johan, additional, Koskenvesa, Perttu, additional, Mustjoki, Satu, additional, Majeed, Waleed, additional, Lübking, Anna, additional, Dreimane, Arta, additional, Markevärn, Berit, additional, Stenke, Leif, additional, Myhr Eriksson, Kristina, additional, Gjertsen, Bjørn Tore, additional, Gedde‐Dahl, Tobias, additional, Dimitrijevic, Andreja, additional, Udby, Lene, additional, Olsson‐Strömberg, Ulla, additional, and Hjorth‐Hansen, Henrik, additional

Published
2021
Full Text
View/download PDF

11. Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry

Author

Flygt, Hjalmar, Sandin, Fredrik, Dahlen, Torsten, Dreimane, Arta, Lubking, Anna, Markevarn, Berit, Myhr-Eriksson, Kristina, Olsson, Karin, Olsson-Stromberg, Ulla, Sjalander, Anders, Soderlund, Stina, Wennstrom, Lovisa, Wadenvik, Hans, Stenke, Leif, Hoglund, Martin, Richter, Johan, Flygt, Hjalmar, Sandin, Fredrik, Dahlen, Torsten, Dreimane, Arta, Lubking, Anna, Markevarn, Berit, Myhr-Eriksson, Kristina, Olsson, Karin, Olsson-Stromberg, Ulla, Sjalander, Anders, Soderlund, Stina, Wennstrom, Lovisa, Wadenvik, Hans, Stenke, Leif, Hoglund, Martin, and Richter, Johan

Abstract

Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure in clinical routine, data on TKI stopping outside clinical trials are limited. In this retrospective study utilising the Swedish CML registry, we examined TKI discontinuation in a population-based setting. Out of 584 patients diagnosed with chronic-phase CML (CML-CP) in 2007-2012, 548 had evaluable information on TKI discontinuation. With a median follow-up of nine years from diagnosis, 128 (23%) discontinued TKI therapy (>= 1 month) due to achieving a DMR (deep molecular response) and 107 (20%) due to other causes (adverse events, allogeneic stem cell transplant, pregnancy, etc). Among those stopping in DMR, 49% re-initiated TKI treatment (median time to restart 4 center dot 8 months). In all, 38 patients stopped TKI within a clinical study and 90 outside a study. After 24 months 41 center dot 1% of patients discontinuing outside a study had re-initiated TKI treatment. TKI treatment duration pre-stop was longer and proportion treated with second-generation TKI slightly higher outside studies, conceivably affecting the clinical outcome. In summary we show that TKI discontinuation in CML in clinical practice is common and feasible and may be just as successful as when performed within a clinical trial.

Published
2021
Full Text
View/download PDF

12. Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study

Author

Flygt, Hjalmar, Söderlund, Stina, Stentoft, Jesper, Richter, Johan, Koskenvesa, Perttu, Mustjoki, Satu, Majeed, Waleed, Lubking, Anna, Dreimane, Arta, Markevarn, Berit, Stenke, Leif, Myhr Eriksson, Kristina, Gjertsen, Bjorn Tore, Gedde-Dahl, Tobias, Dimitrijevic, Andreja, Udby, Lene, Olsson-Strömberg, Ulla, Hjorth-Hansen, Henrik, Flygt, Hjalmar, Söderlund, Stina, Stentoft, Jesper, Richter, Johan, Koskenvesa, Perttu, Mustjoki, Satu, Majeed, Waleed, Lubking, Anna, Dreimane, Arta, Markevarn, Berit, Stenke, Leif, Myhr Eriksson, Kristina, Gjertsen, Bjorn Tore, Gedde-Dahl, Tobias, Dimitrijevic, Andreja, Udby, Lene, Olsson-Strömberg, Ulla, and Hjorth-Hansen, Henrik

Abstract

Objectives Treatment-free remission (TFR) has emerged as a treatment goal in chronic myeloid leukemia in the chronic phase (CML-CP). Attempts to increase proportion of patients achieving TFR include combination of tyrosine kinase inhibitors (TKI) and other drugs. Interferon-alpha in addition to TKI has shown promising efficacy but with dose-dependent toxicity and discontinuations. NordCML007 was initiated to study the efficacy and safety of low dose pegylated IFN-alpha (PegIFN-alpha) in combination with dasatinib (DAS) in CML-CP. Methods Forty patients with newly diagnosed CML-CP were given DAS upfront. After month 3 (M3) 15 mu g/wk of PegIFN-alpha was added and increased to 25 mu g/wk from M7 until M15. DAS treatment was continued and adverse events and BCR-ABL1 qRT-PCR values were reported yearly after M24. Results from M1 to M18 have previously been published, and here we present long-term data. Results After 5 years of follow-up, there were no suspected unexpected serious adverse reactions, no increase in serosal effusions, no disease progressions and no CML-related deaths. Rates of MR3.0 (MMR), MR4.0 and MR4.5 were 84.6%, 64.1% and 51.3% respectively at M60, and 95% of patients reached MMR at some point during the study. Conclusion Initial addition of PegIFN-alpha to DAS shows good long-term efficacy without increased toxicity., Funding Agencies|BMSBristol-Myers Squibb; MSD

Published
2021
Full Text
View/download PDF

13. Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registry

Author

Flygt, Hjalmar, primary, Sandin, Fredrik, additional, Dahlén, Torsten, additional, Dremaine, Arta, additional, Lübking, Anna, additional, Markevärn, Berit, additional, Myhr‐Eriksson, Kristina, additional, Olsson, Karin, additional, Olsson‐Strömberg, Ulla, additional, Själander, Anders, additional, Söderlund, Stina, additional, Wennström, Lovisa, additional, Wadenvik, Hans, additional, Stenke, Leif, additional, Höglund, Martin, additional, and Richter, Johan, additional

Published
2021
Full Text
View/download PDF

14. Early death rates remain high in high-risk APL : update from the Swedish Acute Leukemia Registry 1997-2013

Author

Lehmann, Sören, Deneberg, Stefan, Antunovic, Petar, Rangert-Derolf, Åsa, Garelius, Hege K. G., Lazarevic, Vladimir Lj J., Myhr-Eriksson, Kristina, Möllgård, Lars, Uggla, Bertil, Wåhlin, Anders C. E., Wennström, Lovisa, Höglund, Martin, Juliusson, Gunnar J., Lehmann, Sören, Deneberg, Stefan, Antunovic, Petar, Rangert-Derolf, Åsa, Garelius, Hege K. G., Lazarevic, Vladimir Lj J., Myhr-Eriksson, Kristina, Möllgård, Lars, Uggla, Bertil, Wåhlin, Anders C. E., Wennström, Lovisa, Höglund, Martin, and Juliusson, Gunnar J.

Abstract

All authors are members of Unit of Hematology, Department of Medicine, Karolinska Institute, Huddinge, Stockholm, Sweden

Published
2017
Full Text
View/download PDF

15. Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden

Author

Juliusson, Gunnar J., Abrahamsson, Jonas, Lazarevic, Vladimir Lj. J., Antunovic, Petar, Derolf, Åsa Rangert, Garelius, Hege K. G., Lehmann, Sören, Myhr-Eriksson, Kristina, Möllgård, Lars, Uggla, Bertil, Wahlin, Anders C. E., Wennström, Lovisa, Höglund, Martin, Swedish AML Group, Group author, Swedish Childhood Leukemia Group, Group Author, Juliusson, Gunnar J., Abrahamsson, Jonas, Lazarevic, Vladimir Lj. J., Antunovic, Petar, Derolf, Åsa Rangert, Garelius, Hege K. G., Lehmann, Sören, Myhr-Eriksson, Kristina, Möllgård, Lars, Uggla, Bertil, Wahlin, Anders C. E., Wennström, Lovisa, Höglund, Martin, Swedish AML Group, Group author, and Swedish Childhood Leukemia Group, Group Author

Published
2017
Full Text
View/download PDF

16. Effects of Dasatinib and Interferon-α Combination Treatment on the Immune System in CML

Author

Ilander, Mette, primary, Lähteenmäki, Hanna, additional, Olsson-Stromberg, Ulla, additional, Stentoft, Jesper, additional, Richter, Johan, additional, Koskenvesa, Perttu, additional, Höglund, Martin, additional, Dreimane, Arta, additional, Porkka, Kimmo, additional, Gedde-Dahl, Tobias, additional, Gjertsen, Björn T., additional, Gruber, Franz X., additional, Stenke, Leif, additional, Myhr-Eriksson, Kristina, additional, Markevärn, Berit, additional, Lubking, Anna, additional, Vestergaard, Hanne, additional, Udby, Lene, additional, Weis Bjerrum, Ole, additional, Hjorth-Hansen, Henrik, additional, and Mustjoki, Satu, additional

Published
2016
Full Text
View/download PDF

17. Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Author

Hjorth-Hansen, Henrik, Stentoft, Jesper, Richter, Johan, Koskenvesa, Perttu, Dreimane, Arta, Porkka, Kimmo, Gedde-Dahl, Tobias, Gjertsen, Bjorn, Gruber, Franz X., Höglund, Martin, Lubking, Anna, Myhr-Eriksson, Kristina, Markevarn, Berit, Vestergaard, Hanne, Bjerrurn, Ole Weis, Stenke, Leif, Mustjoki, Satu, Strömberg, Ulla, Hjorth-Hansen, Henrik, Stentoft, Jesper, Richter, Johan, Koskenvesa, Perttu, Dreimane, Arta, Porkka, Kimmo, Gedde-Dahl, Tobias, Gjertsen, Bjorn, Gruber, Franz X., Höglund, Martin, Lubking, Anna, Myhr-Eriksson, Kristina, Markevarn, Berit, Vestergaard, Hanne, Bjerrurn, Ole Weis, Stenke, Leif, Mustjoki, Satu, and Strömberg, Ulla

Published
2015

18. Prevalence and Characteristics of Survivors from Adult Acute Myeloid Leukemia (AML) in Sweden 2014

Author

Juliusson, Gunnar, Lazarevic, Vladimir, Antunovic, Petar, Derolf, Asa Rangert, Garelius, Hege, Lehmann, Sören, Myhr-Eriksson, Kristina, Mollgard, Lars, Uggla, Bertil, Wahlin, Anders, Wennstrom, Lovisa, Höglund, Martin, Juliusson, Gunnar, Lazarevic, Vladimir, Antunovic, Petar, Derolf, Asa Rangert, Garelius, Hege, Lehmann, Sören, Myhr-Eriksson, Kristina, Mollgard, Lars, Uggla, Bertil, Wahlin, Anders, Wennstrom, Lovisa, and Höglund, Martin

Published
2015

19. Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Author

Hjorth-Hansen, Henrik, primary, Stentoft, Jesper, additional, Richter, Johan, additional, Koskenvesa, Perttu, additional, Dreimane, Arta, additional, Porkka, Kimmo, additional, Gedde-Dahl, Tobias, additional, Gjertsen, Bjorn, additional, Gruber, Franz X., additional, Hoglund, Martin, additional, Lubking, Anna, additional, Myhr-Eriksson, Kristina, additional, Markevärn, Berit, additional, Vestergaard, Hanne, additional, Weis Bjerrum, Ole, additional, Stenke, Leif, additional, Mustjoki, Satu, additional, and Stromberg, Ulla, additional

Published
2015
Full Text
View/download PDF

20. Prevalence and Characteristics of Survivors from Adult Acute Myeloid Leukemia (AML) in Sweden 2014

Author

Juliusson, Gunnar, primary, Lazarevic, Vladimir, additional, Antunovic, Petar, additional, Derolf, Asa Rangert, additional, Garelius, Hege, additional, Lehmann, Sören, additional, Myhr-Eriksson, Kristina, additional, Möllgård, Lars, additional, Uggla, Bertil, additional, Wahlin, Anders, additional, Wennström, Lovisa, additional, and Höglund, Martin, additional

Published
2015
Full Text
View/download PDF

21. Allogeneic Transplantation in First Remission Improves Outcome in Secondary Acute Myeloid Leukemia

Author

Nilsson, Christer, Hulegardh, Erik, Lazarevic, Vladimir, Garelius, Hege, Derolf, Asa Rangert, Mollgard, Lars, Wennstrom, Lovisa, Uggla, Bertil, Antunovic, Petar, Myhr-Eriksson, Kristina, Wahlin, Anders, Höglund, Martin, Juliusson, Gunnar, Stockelberg, Dick, Soren, Lehmann, Nilsson, Christer, Hulegardh, Erik, Lazarevic, Vladimir, Garelius, Hege, Derolf, Asa Rangert, Mollgard, Lars, Wennstrom, Lovisa, Uggla, Bertil, Antunovic, Petar, Myhr-Eriksson, Kristina, Wahlin, Anders, Höglund, Martin, Juliusson, Gunnar, Stockelberg, Dick, and Soren, Lehmann

Published
2014

22. Improved Survival of Patients with Acute Myeloid Leukemia Following Implementation of Swedish National Guidelines : Results from the AML Registry 1997-2013

Author

Juliusson, Gunnar, Lazarevic, Vladimir, Lehmann, Soren, Derolf, Asa Rangert, Mollgard, Lars, Garelius, Hege, Wennstrom, Lovisa, Uggla, Bertil, Antunovic, Petar, Myhr-Eriksson, Kristina, Wahlin, Anders, Höglund, Martin, Juliusson, Gunnar, Lazarevic, Vladimir, Lehmann, Soren, Derolf, Asa Rangert, Mollgard, Lars, Garelius, Hege, Wennstrom, Lovisa, Uggla, Bertil, Antunovic, Petar, Myhr-Eriksson, Kristina, Wahlin, Anders, and Höglund, Martin

Published
2014

23. Improved Survival of Patients with Acute Myeloid Leukemia Following Implementation of Swedish National Guidelines: Results from the AML Registry 1997-2013

Author

Juliusson, Gunnar, primary, Lazarevic, Vladimir, additional, Lehmann, Sören, additional, Derolf, Åsa Rangert, additional, Möllgård, Lars, additional, Garelius, Hege, additional, Wennström, Lovisa, additional, Uggla, Bertil, additional, Antunovic, Petar, additional, Myhr-Eriksson, Kristina, additional, Wahlin, Anders, additional, and Höglund, Martin, additional

Published
2014
Full Text
View/download PDF

24. Allogeneic Transplantation in First Remission Improves Outcome in Secondary Acute Myeloid Leukemia

Author

Nilsson, Christer, primary, Hulegårdh, Erik, additional, Lazarevic, Vladimir, additional, Garelius, Hege, additional, Derolf, Asa Rangert, additional, Möllgård, Lars, additional, Wennström, Lovisa, additional, Uggla, Bertil, additional, Antunovic, Petar, additional, Myhr-Eriksson, Kristina, additional, Wahlin, Anders, additional, Höglund, Martin, additional, Juliusson, Gunnar, additional, Stockelberg, Dick, additional, and Soren, Lehmann, additional

Published
2014
Full Text
View/download PDF

26. Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Author

Simonsson, Bengt, Gedde-Dahl, Tobias, Markevarn, Berit, Remes, Kari, Stentoft, Jesper, Almqvist, Anders, Bjoreman, Mats, Flogegard, Max, Koskenvesa, Perttu, Lindblom, Anders, Malm, Claes, Mustjoki, Satu, Myhr-Eriksson, Kristina, Ohm, Lotta, Rasanen, Anu, Sinisalo, Marjatta, Sjalander, Anders, Strömberg, Ulla, Bjerrum, Ole Weiss, Ehrencrona, Hans, Gruber, Franz, Kairisto, Veli, Olsson, Karin, Sandin, Fredrik, Nagler, Arnon, Nielsen, Johan Lanng, Hjorth-Hansen, Henrik, Porkka, Kimmo, Simonsson, Bengt, Gedde-Dahl, Tobias, Markevarn, Berit, Remes, Kari, Stentoft, Jesper, Almqvist, Anders, Bjoreman, Mats, Flogegard, Max, Koskenvesa, Perttu, Lindblom, Anders, Malm, Claes, Mustjoki, Satu, Myhr-Eriksson, Kristina, Ohm, Lotta, Rasanen, Anu, Sinisalo, Marjatta, Sjalander, Anders, Strömberg, Ulla, Bjerrum, Ole Weiss, Ehrencrona, Hans, Gruber, Franz, Kairisto, Veli, Olsson, Karin, Sandin, Fredrik, Nagler, Arnon, Nielsen, Johan Lanng, Hjorth-Hansen, Henrik, and Porkka, Kimmo

Abstract

Biologic and clinical observations suggest that combining imatinib with IFN-alpha may improve treatment outcome in chronic myeloid leukemia (CML). We randomized newly diagnosed chronic-phase CML patients with a low or intermediate Sokal risk score and in imatinib-induced complete hematologic remission either to receive a combination of pegylated IFN-alpha 2b (Peg-IFN-alpha 2b) 50 mu g weekly and imatinib 400 mg daily (n = 56) or to receive imatinib 400 mg daily monotherapy (n = 56). The primary endpoint was the major molecular response (MMR) rate at 12 months after randomization. In both arms, 4 patients (7%) discontinued imatinib treatment (1 because of blastic transformation in imatinib arm). In addition, in the combination arm, 34 patients (61%) discontinued Peg-IFN-alpha 2b, most because of toxicity. The MMR rate at 12 months was significantly higher in the imatinib plus Peg-IFN-alpha 2b arm (82%) compared with the imatinib monotherapy arm (54%; intention-to-treat, P = .002). The MMR rate increased with the duration of Peg-IFN-alpha 2b treatment (< 12-week MMR rate 67%, > 12-week MMR rate 91%). Thus, the addition of even relatively short periods of Peg-IFN-alpha 2b to imatinib markedly increased the MMR rate at 12 months of therapy. Lower doses of Peg-IFN-alpha 2b may enhance tolerability while retaining efficacy and could be considered in future protocols with curative intent.

Published
2011
Full Text
View/download PDF

27. A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy. in BLOOD, vol 114, issue 22, pp 1269-1270

Author

Simonsson, Bengt, Gedde-Dahl, Tobias, Markevarn, Berit, Remes, Kari, Stentoft, Jesper, Almqvist, Anders, Bjoreman, Mats, Flogegard, Max, Hallman, Heikki, Koskenvesa, Perttu, Lindblom, Anders, Malm, Claes, Mustjoki, Satu, Myhr-Eriksson, Kristina, Rasanen, Anu, Sinisalo, Marjatta, Sippola, Risto, Sjalander, Anders, Stromberg, Ulla, Weiss Bjerrum, Ole, Ehrencrona, Hans, Gruber, Franz, Kairisto, Veli, Olsson, Karin, Nagler, Arnon, Lanng Nielsen, Johan, Hjorth-Hansen, Henrik, Porkka, Kimmo, Simonsson, Bengt, Gedde-Dahl, Tobias, Markevarn, Berit, Remes, Kari, Stentoft, Jesper, Almqvist, Anders, Bjoreman, Mats, Flogegard, Max, Hallman, Heikki, Koskenvesa, Perttu, Lindblom, Anders, Malm, Claes, Mustjoki, Satu, Myhr-Eriksson, Kristina, Rasanen, Anu, Sinisalo, Marjatta, Sippola, Risto, Sjalander, Anders, Stromberg, Ulla, Weiss Bjerrum, Ole, Ehrencrona, Hans, Gruber, Franz, Kairisto, Veli, Olsson, Karin, Nagler, Arnon, Lanng Nielsen, Johan, Hjorth-Hansen, Henrik, and Porkka, Kimmo

Abstract

n/a

Published
2009

28. A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.

Author

Simonsson, Bengt, Gedde-Dahl, Tobias, Markevärn, Berit, Remes, Kari, Stentoft, Jesper, Almqvist, Anders, Björeman, Mats, Flogegård, Max, Hallman, Heikki, Koskenvesa, Perttu, Lindblom, Anders, Malm, Claes, Mustjoki, Satu, Myhr-Eriksson, Kristina, Räsänen, Anu, Sinisalo, Marjatta, Sippola, Risto, Själander, Anders, Strömberg, Ulla, Bjerrum, Ole Weiss, Ehrencrona, Hans, Gruber, Franz, Kairisto, Veli, Olsson, Karin RN, Nagler, Arnon, Nielsen, Johan Lanng, Hjorth-Hansen, Henrik, Porkka, Kimmo, and for the Nordic CML Study Group (NCMLSG)

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results